| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4285129 | Formosan Journal of Surgery | 2012 | 6 Pages |
SummaryObjectiveTo investigate the role of postoperative chemoradiotherapy in locally advanced esophageal cancer after primary surgery.MethodsForty-one patients with locally advanced esophageal cancer (30/41 pathologic Stage IIIA-C, 73.2%) who underwent radical surgery and complete postoperative chemoradiotherapy between May 2004 and May 2010 were enrolled. The radiotherapy was delivered by the intensity-modulated radiotherapy technique. Concurrently, chemotherapy with cisplatin and 5-fluorouracil was given on the 1st week and the 5th week of radiotherapy. The overall survival, disease-free survival, and local recurrence rate were calculated to determine the role of postoperative radiotherapy in locally advanced esophageal cancer. Univariate analysis was used to elucidate the prognostic risk factors.ResultsAfter a median follow-up of 34.5 months (range, 3–87 months), the median overall survival was 13 months. The 1-year and 3-year overall survival rates were 61.0 % and 24.6%, respectively. The disease free survival after 1 year and 3 year was 42.8% and 28.1%, respectively. There was a significant difference in survival between the patients who had N0/1 and N2/3 disease by univariate analysis with 1-year survival and median survival rates of 66.7% versus 37.5% and 17 months versus 10.5 months, respectively (p = 0.036). The local recurrence rate was 17.1 % (7/41) at 3 years. Acute treatment-related toxicities were mild. Most of the patients died of distant metastasis.ConclusionPostoperative chemoradiotherapy showed a mild acute treatment-related toxicity and a relatively good local control but these effects did not contribute a higher survival rate to patients with advanced esophageal cancer.
